National CAR T-cell network heralds a big win for patients

Sponsored by Novartis Pharmaceuticals Australia Pty Ltd

Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy where a patient’s own T-cells are genetically altered to directly target cancer cells.1 By reprogramming autologous T-cells to express CARs, the receptors combine the effector functions of T-cells with the ability of antibodies to recognise tumour surface antigens with high specificity.1 In January 2020, ...

Already a member?

Login to keep reading.

© 2021 the limbic